The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients

Yeohan Song, Julie H Y Tai, Sarah Bartsch, Richard K. Zimmerman, Robert R. Muder, Bruce Lee

Research output: Contribution to journalArticle

Abstract

Staphylococcus aureus infections are a substantial problem for hemodialysis patients. Several vaccine candidates are currently under development, with hemodialysis patients being one possible target population. To determine the potential economic value of an S. aureus vaccine among hemodialysis patients, we developed a Markov decision analytic computer simulation model. When S. aureus colonization prevalence was 1%, the incremental cost-effectiveness ratio (ICER) of vaccination was ≤$25,217/quality-adjusted life year (QALY). Vaccination became more cost-effective as colonization prevalence, vaccine efficacy, or vaccine protection duration increased or vaccine cost decreased. Even at 10% colonization prevalence, a 25% efficacious vaccine costing $100 prevented 29 infections, 21 infection-related hospitalizations, and 9 inpatient deaths per 1000 vaccinated HD patients. Our results suggest that an S. aureus vaccine would be cost-effective (i.e., ICERs ≤ $50,000/QALY) among hemodialysis patients over a wide range of S. aureus prevalence, vaccine costs and efficacies, and vaccine protection durations and delineate potential target parameters for such a vaccine.

Original languageEnglish (US)
Pages (from-to)3675-3682
Number of pages8
JournalVaccine
Volume30
Issue number24
DOIs
StatePublished - May 21 2012
Externally publishedYes

Fingerprint

hemodialysis
economic valuation
Renal Dialysis
Staphylococcus aureus
Vaccines
Economics
vaccines
quality-adjusted life year
Costs and Cost Analysis
Quality-Adjusted Life Years
Computer Simulation
Vaccination
Infection
vaccination
infection
duration
Health Services Needs and Demand
cost effectiveness
computer simulation
Cost-Benefit Analysis

Keywords

  • Cost-effectiveness
  • Economics
  • Hemodialysis
  • Staphylococcus aureus
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients. / Song, Yeohan; Tai, Julie H Y; Bartsch, Sarah; Zimmerman, Richard K.; Muder, Robert R.; Lee, Bruce.

In: Vaccine, Vol. 30, No. 24, 21.05.2012, p. 3675-3682.

Research output: Contribution to journalArticle

Song, Yeohan ; Tai, Julie H Y ; Bartsch, Sarah ; Zimmerman, Richard K. ; Muder, Robert R. ; Lee, Bruce. / The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients. In: Vaccine. 2012 ; Vol. 30, No. 24. pp. 3675-3682.
@article{45cabc4e21a34262944e1697c50b1907,
title = "The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients",
abstract = "Staphylococcus aureus infections are a substantial problem for hemodialysis patients. Several vaccine candidates are currently under development, with hemodialysis patients being one possible target population. To determine the potential economic value of an S. aureus vaccine among hemodialysis patients, we developed a Markov decision analytic computer simulation model. When S. aureus colonization prevalence was 1{\%}, the incremental cost-effectiveness ratio (ICER) of vaccination was ≤$25,217/quality-adjusted life year (QALY). Vaccination became more cost-effective as colonization prevalence, vaccine efficacy, or vaccine protection duration increased or vaccine cost decreased. Even at 10{\%} colonization prevalence, a 25{\%} efficacious vaccine costing $100 prevented 29 infections, 21 infection-related hospitalizations, and 9 inpatient deaths per 1000 vaccinated HD patients. Our results suggest that an S. aureus vaccine would be cost-effective (i.e., ICERs ≤ $50,000/QALY) among hemodialysis patients over a wide range of S. aureus prevalence, vaccine costs and efficacies, and vaccine protection durations and delineate potential target parameters for such a vaccine.",
keywords = "Cost-effectiveness, Economics, Hemodialysis, Staphylococcus aureus, Vaccine",
author = "Yeohan Song and Tai, {Julie H Y} and Sarah Bartsch and Zimmerman, {Richard K.} and Muder, {Robert R.} and Bruce Lee",
year = "2012",
month = "5",
day = "21",
doi = "10.1016/j.vaccine.2012.03.031",
language = "English (US)",
volume = "30",
pages = "3675--3682",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "24",

}

TY - JOUR

T1 - The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients

AU - Song, Yeohan

AU - Tai, Julie H Y

AU - Bartsch, Sarah

AU - Zimmerman, Richard K.

AU - Muder, Robert R.

AU - Lee, Bruce

PY - 2012/5/21

Y1 - 2012/5/21

N2 - Staphylococcus aureus infections are a substantial problem for hemodialysis patients. Several vaccine candidates are currently under development, with hemodialysis patients being one possible target population. To determine the potential economic value of an S. aureus vaccine among hemodialysis patients, we developed a Markov decision analytic computer simulation model. When S. aureus colonization prevalence was 1%, the incremental cost-effectiveness ratio (ICER) of vaccination was ≤$25,217/quality-adjusted life year (QALY). Vaccination became more cost-effective as colonization prevalence, vaccine efficacy, or vaccine protection duration increased or vaccine cost decreased. Even at 10% colonization prevalence, a 25% efficacious vaccine costing $100 prevented 29 infections, 21 infection-related hospitalizations, and 9 inpatient deaths per 1000 vaccinated HD patients. Our results suggest that an S. aureus vaccine would be cost-effective (i.e., ICERs ≤ $50,000/QALY) among hemodialysis patients over a wide range of S. aureus prevalence, vaccine costs and efficacies, and vaccine protection durations and delineate potential target parameters for such a vaccine.

AB - Staphylococcus aureus infections are a substantial problem for hemodialysis patients. Several vaccine candidates are currently under development, with hemodialysis patients being one possible target population. To determine the potential economic value of an S. aureus vaccine among hemodialysis patients, we developed a Markov decision analytic computer simulation model. When S. aureus colonization prevalence was 1%, the incremental cost-effectiveness ratio (ICER) of vaccination was ≤$25,217/quality-adjusted life year (QALY). Vaccination became more cost-effective as colonization prevalence, vaccine efficacy, or vaccine protection duration increased or vaccine cost decreased. Even at 10% colonization prevalence, a 25% efficacious vaccine costing $100 prevented 29 infections, 21 infection-related hospitalizations, and 9 inpatient deaths per 1000 vaccinated HD patients. Our results suggest that an S. aureus vaccine would be cost-effective (i.e., ICERs ≤ $50,000/QALY) among hemodialysis patients over a wide range of S. aureus prevalence, vaccine costs and efficacies, and vaccine protection durations and delineate potential target parameters for such a vaccine.

KW - Cost-effectiveness

KW - Economics

KW - Hemodialysis

KW - Staphylococcus aureus

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84860991000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860991000&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.03.031

DO - 10.1016/j.vaccine.2012.03.031

M3 - Article

VL - 30

SP - 3675

EP - 3682

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 24

ER -